Can thrombocytosis contribute to dizziness in a patient?

Can Elevated Platelet Count Contribute to Dizziness?

Yes, elevated platelet counts can directly cause dizziness and other neurological symptoms through microvascular occlusion, particularly in the context of myeloproliferative neoplasms like essential thrombocythemia (ET) and polycythemia vera (PV).

Mechanism and Clinical Presentation

Thrombocytosis causes dizziness through platelet-mediated microvascular dysfunction rather than through major vessel thrombosis. The pathophysiology involves shear rate-induced intravascular platelet activation and aggregation, leading to transient sludging or occlusion of cerebral arterial microvasculature 1.

Specific Neurological Manifestations in Thrombocytosis:

• Microcirculatory symptoms including headaches, lightheadedness, and acral paresthesias are characteristic presenting features 2, 3
• Brief attacks of sudden cerebral or visual dysfunction that can be either well-localized or diffuse and nonspecific 1
• Dull, throbbing headaches lasting several hours frequently accompany neurological symptoms 1
• Visual symptoms including transient monocular blindness, scintillating scotomas, and blurred vision 1

Evidence from Myeloproliferative Disorders

Balance disturbances are among the most common symptoms in chronic myeloproliferative disorders with high platelet counts 4. In a study of 43 patients with ET and PV:

• 60.4% showed exclusive central vestibular involvement
• 18.6% had combined peripheral and central signs
• Only 14% had normal otoneurologic examination 4

The high percentage of balance disorders likely depends on microcirculation disturbances due to platelet dysfunction, with central vestibular system involvement explained by increased central activated serotonin acting as a neuromediator 4.

Critical Distinction: Extreme vs. Moderate Thrombocytosis

Important caveat: The relationship between platelet count and symptoms is paradoxical in myeloproliferative neoplasms. According to NCCN guidelines, thrombocytosis >1,000 × 10⁹/L is associated with major hemorrhage risk but NOT with increased thrombosis risk 5. In fact, some studies show that extremely elevated platelet counts (>1,000 × 10⁹/L) are associated with significantly lower rates of thrombosis 5.

When to Suspect Primary vs. Secondary Thrombocytosis:

Primary thrombocytosis (ET/PV) presents with:

• Persistent platelet count ≥450 × 10⁹/L 3
• Microvascular symptoms (headaches, dizziness, paresthesias, erythromelalgia) 2, 3
• JAK2, CALR, or MPL mutations in ~80% of cases 2
• Bone marrow showing increased mature megakaryocytes in loose clusters 2

Secondary (reactive) thrombocytosis:

• Usually benign and asymptomatic 6
• Resolves with treatment of underlying condition 3
• Does NOT cause thromboembolic complications 6

Management Algorithm for Dizziness with Thrombocytosis

Step 1: Confirm Persistent Thrombocytosis

• Repeat CBC with differential and peripheral blood smear 3
• Check C-reactive protein and iron studies with ferritin 3

Step 2: Identify Underlying Cause

• If secondary cause identified (infection, inflammation, iron deficiency): treat underlying condition
• If no secondary cause and platelets persistently ≥450 × 10⁹/L: test for JAK2, then CALR and MPL mutations 3
• Perform bone marrow biopsy if myeloproliferative neoplasm suspected 3

Step 3: Immediate Treatment for Symptomatic Patients

For microvascular symptoms (including dizziness) in ET/PV:

• Low-dose aspirin (81-100 mg daily) is strikingly effective and completely abolishes ischemic neurological attacks in ET 1, 5
• Consider twice-daily aspirin for low-risk disease with persistent symptoms 2
• Symptoms typically respond within days to aspirin therapy 1

For extreme thrombocytosis (>1,500 × 10⁹/L) with symptoms:

• Consider interferon alfa for cytoreduction 7
• Therapeutic plateletpheresis can achieve dramatic symptom relief: 67% platelet reduction with simultaneous improvement in symptoms including giddiness and headache 8

Step 4: Long-term Management Based on Risk Stratification

Use the revised International Prognostic Score of Thrombosis for ET (IPSET-Thrombosis) 5:

Very low-risk (age ≤60, no JAK2 mutation, no thrombosis history):

• Observation or aspirin for vascular symptoms 5

Low-risk (age ≤60, JAK2 mutation present, no thrombosis history):

• Aspirin 81-100 mg daily 5
• Initiate cytoreductive therapy if symptomatic thrombocytosis or vasomotor disturbances not responsive to aspirin 5

High-risk (age >60 with JAK2 mutation OR thrombosis history):

• Cytoreductive therapy with hydroxyurea as first-line agent 2, 3
• Pegylated interferon-α as alternative first-line option 2
• Low-dose aspirin unless contraindicated 2

Common Pitfalls to Avoid

1. Do not assume all thrombocytosis is benign: While secondary thrombocytosis is common and benign 6, primary thrombocytosis requires specific treatment to prevent complications

2. Do not withhold aspirin based on platelet count alone: The striking efficacy of low-dose aspirin for microvascular symptoms is well-established 1, and bleeding risk is actually higher with extreme thrombocytosis (>1,000 × 10⁹/L) due to acquired von Willebrand disease 5

3. Do not confuse with other causes of dizziness: Consider thrombotic thrombocytopenic purpura (TTP) if patient has fever, hemolytic anemia, thrombocytopenia (not thrombocytosis), renal dysfunction, and neurological symptoms 9, 10

4. Do not delay treatment in symptomatic patients: Platelet-mediated microvascular symptoms respond rapidly to aspirin therapy and should be treated promptly 1